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Background: Obesity, type 2 diabetes and atrial fibrillation (AF) are closely associated, but the underlying mechanisms
are not fully understood. We aimed to explore associations between body mass index (BMI) or weight change with risk
of AF in patients with type 2 diabetes.
Methods: A total of 7,169 participations with newly diagnosed type 2 diabetes were stratified according to baseline
BMI, and after a second BMI measurement within 18 months, further grouped according to relative weight change as
“weight gain” (>1 BMI unit), “stable weight” (+/− 1 BMI unit) and “weight loss” (<1 BMI unit). The mean follow-up period
was 4.6 years, and the risk of AF was estimated using adjusted Cox regression models.
Results: Average age at diabetes diagnosis was 60 years and the patients were slightly obese (mean BMI 30.2 kg/m2).
During follow-up, 287 patients developed incident AF, and those with overweight or obesity at baseline had 1.9-fold
and 2.9-fold higher risk of AF, respectively, than those with normal BMI. The 14% of the patients with subsequent
weight gain had 1.5-fold risk of AF compared with those with stable weight or weight loss.
Conclusions: In patients with newly diagnosed type 2 diabetes, baseline overweight and obesity, as well as modest
weight increase during the first 18 months after diagnosis, were associated with a substantially increased risk of
incident AF. Patients with type 2 diabetes may benefit from efforts to prevent weight gain in order to reduce the risk
of incident AF.
Trial registration: ClinicalTrials.gov: NCT01121315
Keywords: Epidemiology, Atrial fibrillation, Type 2 diabetes, Weight controlIntroduction
The increasing prevalence and close co-existence of
obesity, type 2 diabetes and atrial fibrillation (AF) rep-
resents a current and future health challenge [1-7].
Patients with type 2 diabetes and obesity are at high risk
of cardiovascular diseases, and the additional occurrence
of AF adds further to their burden of disease and increases
pressure on the health care system [8]. The underlying
interrelations are not fully understood, but both obesity
and diabetes may cause atrial remodelling, influencing AF
substrate [9-12]. In one study, the well-known obesity-AF* Correspondence: uxirgr@ous-hf.no
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unless otherwise stated.association seemed to be mediated partially by the pres-
ence of diabetes [13]. Also after adjusting for known risk
factors, including body mass index (BMI), incident AF
appears more common in diabetic patients, suggesting
additional effects of e.g. insulin resistance, inflammation
or autonomic changes, which may act as AF mediators
[14-18]. However, the importance of body weight for the
AF burden in diabetes is not well characterized.
We hypothesized that higher BMI and subsequent
weight gain following the diagnosis of type 2 diabetes,
were associated with increased AF risk. We aimed to
explore this in a large primary care based cohort of
patients newly diagnosed with type 2 diabetes.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Study population
This was an observational cohort study based on the
“Retrospective Epidemiological Study to Investigate Out-
come and Mortality with Glucose Lowering Drug Treat-
ment in Primary Care” (ROSE) study [19]. In 2010,
patient data were extracted from 84 primary care centers
in Sweden, representing 8% of the total centers, by the
Pygargus Customized eXtraction Program. Data on all
patients having a diagnosis of either type 2 diabetes and/
or a prescription of glucose lowering drugs between
1999 and 2009 were extracted, as described in detail
elsewhere [20,21]. Patients were excluded from the study
cohort if; they had a previous history of diabetes from
the medical records, were aged <35 years or >79 years,
had active cancer or previous cardiovascular disease
(CVD), or missing data on BMI at baseline and within 1
1/2 year after the diabetes diagnosis. They were also
excluded if they developed CVD (including AF) or cancer
during the time between the two BMI measurements.
Patients with stable angina pectoris (AP) were allowed to
participate. To minimize the risk of previously undetected
AF, we included only patients that had established a first
contact at their respective primary care centres minimum
15 months before baseline. Finally, 7,169 patients with
newly diagnosed type 2 diabetes, but without comorbidity
as mentioned above, and with regular contact with the
health system, were eligible for the present analysis.
Baseline data, extracted from electronic patient charts,
included systolic and diastolic blood pressure (BP), chol-
esterol, HbA1c and creatinine, as well as lipid lowering,
glucose lowering and BP-lowering drugs. Baseline values
were calculated as means of the last three measures
within 15 months prior to and 14 days after the date of
the diabetes diagnosis. Baseline BMI was defined as the
measurement closest to the date of new-onset diabetes,
restricted to the interval from 15 months prior to and
within 45 days after diagnosis. BMI was analysed both
in quintiles and in groups according to the World
Health Organisation’s classification: normal weight (BMI
18.5-24.9), overweight (BMI 25–29.9) and obesity (BMI ≥
30 kg/m2) [22].
The second or “within 1.5-year” BMI was identified in
the interval between 46 days and 18 months after the
diagnosis of type 2 diabetes, choosing the latest value if
several measurements were available. Very few patients
(4%) had less than 120 days between baseline and second
BMI measurements. The mean time period between the
two BMI measurements were 421 days (±120) for the
weight gain group, 396 days (±134) for the stable weight
group and 402 days (134) for the weight loss group. BMI
change was calculated by subtracting baseline BMI from
the second BMI. The participants were stratified accord-
ing to a relative weight change of 1 BMI unit or more (onaverage ~3.6 kg in this cohort) in the following groups;
weight gain (>1 BMI unit), stable weight (+/− 1 BMI unit)
and weight loss (<1 BMI unit).
Follow-up
The endpoint, incident AF, was documented by linking
the participants’ unique personal identification number to
validated national health registries and electronic patient
records from the primary care centers. Incident AF in-
cludes both atrial fibrillation and flutter as they shared the
same code number in the International Statistical Classifi-
cation of Diseases system. We were unable to differentiate
between paroxysmal, persistent or permanent AF.
The follow-up time started after the second BMI
measurement for each patient and all were followed to
the first event of AF, death or Dec 31th 2009. The study,
complying with the Helsinki declaration, was approved
by the Regional Ethical Review Board, Uppsala, Sweden.
Statistical methods
Differences in baseline data were tested with Student’s t-
test and Pearson Chi-square test according to data type.
The risk of incident AF was estimated using Cox propor-
tional hazard analyses. A regression spline model was used
to assess the shape of the association between baseline
BMI as a continuous variable, and incident AF. Two
adjustment models were chosen to assess the risk of inci-
dent AF related to weight change groups – Model A: Age,
gender, BMI at baseline and previous AP and model B:
Model A + systolic BP. Previous AP was included due to
significant differences in baseline data. In model B, miss-
ing baseline systolic BP data were imputed, which involves
calculating average results over a set of imputed datasets
by using Gibbs sampler and predictive mean matching.
Directed acyclic graphs (DAGs) were used to minimize
the risk of bias and to identify a primary adjustment
model [23]. Additionally, we analysed the association
between weight change and incident AF in a sub-sample
of patients with BMI ≥30 kg/m2 at baseline. The propor-
tional hazards assumptions were assessed by examining
Schoenfeld residuals. The statistical package R, version
2.15.3, was used for all analyses. P-values and confidence
intervals (CI) were two-tailed and on the 95% confidence
level.
Results
Average age was 60 years, 55% were men and mean BMI
was 30.2 kg/m2 at baseline. Table 1 shows the baseline
characteristics by weight change categories. Most patients
had stable weight (52%) and more patients had a decrease
(34%) than an increase (14%) in relative weight. The mean
time between baseline- and second BMI was 1.3 years;
hence for simplicity we have called the second measure-
ment “within 1.5-year” BMI. Patients with weigth gain
Table 1 Characteristics of patients with type 2 diabetes related to weight changes within 18 months after diagnosis
Weight gain Stable weight Weight loss
(n = 1023) (n = 3736) (n = 2410)
Age, years 58.0 (10.3)*** 60.0 (10.2) 59.3 (10.4)**
Men, n (%) 578 (56.5) 2142 (57.3) 1095 (45.4)***
BMI, kg/m2 30.3 (5.8) 30.3 (5.1) 32.8 (5.8)***
BMI ”1.5-year” 32.4 (6.1)*** 30.2 (5.1) 30.3 (5.5)
HbA1c, % 6.5 (0.8)*** 6.7 (0.8) 6.9 (0.8)***
Cholesterol, mmol/l 5.7 (1.2) 5.6 (1.1) 5.7 (1.2)
LDL, mmol/l 3.5 (1.0) 3.5 (0.9) 3.5 (1.0)
HDL, mmol/l 1.5 (0.9) 1.4 (0.8) 1.4 (0.8)
Triglycerides, mmol/l 2.3 (2.2) 2.2 (1.6) 2.3 (2.0)*
Systolic BP, mmHg 145.5 (17.9) 145.7 (17.6) 147.4 (17.5)***
Diastolic BP, mmHg 84.0 (9.3) 83.3 (9.4) 84.7 (9.2)***
Creatinine, mmol/l 78.2 (18.0)* 79.5 (17.0) 78.4 (18.7)*
Estimated GFR, ml/min 85.3 (17.5)*** 83.0 (16.8) 82.5 (17.5)
Angina pectoris, n (%) 38 (3.7)* 206 (5.5) 99 (4.1)*
All numbers are means (±1 standard deviation) or numbers (percent). Significant difference from the group with stable weight: *p < 0.05, **p < 0.01, ***p < 0.001,
BMI = Body mass index, LDL = Low density lipoprotein, HDL = High density lipoprotein, BP = Blood pressure, GFR = Glomerular filtration rate.
Figure 1 Shows BMI at baseline and during follow-up according
to weight change groups during the first 18 months after
diabetes diagnosis.
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had lower HbA1c levels compared to the stable weight
group. Patients who lost weight were more often women
with higher baseline BMI , HbA1c and BP compared to
the stable group. A history of AP was less prevalent in
both the weight gain and the weight loss groups compared
to the stable weight group. Approximately 1/3 of the
patients were initiated on at least one glucose lowering
drug at the time of diabetes diagnosis. More patients were
initiated on sulfonylurea and insulin and fewer on metfor-
min in the weight gain group compared to the stable
weight group (Additional file 1: Table S1). Patients were
followed for up to 9 years, with median follow-up time of
4.6 years (38,300 patient-years). After the initial BMI
changes, the stable weight and weight gain groups showed
a steady decline in BMI, whereas the BMI trend was
essentially unchanged in the weight loss group during
follow-up. Both the weight gain and weight loss groups
remained at higher BMI levels compared to the stable
weight group, with the highest levels consistently found in
the weight gain group (Figure 1).
BMI at baseline and AF risk
During the follow-up period 287 patients developed inci-
dent AF. The risk of AF increased gradually with higher
baseline BMI groups or BMI quintiles. When exploring
the relationship between adjusted AF risk and baseline
BMI using a cubic spline model, a near linear relationship
was found showing increased AF risk with increasing BMI
(detailed data not shown). The adjusted risk of AF was 1.9
(95% CI 1.1-3.1) and 2.9 (1.7- 4.7) for the overweight and
obesity groups, respectively, compared with the patientswith normal BMI (Table 2 and Figure 2). Correspondingly,
the BMI quintiles showed a gradually risk increase of AF
with hazard ratio 3.5 (2.3-5.4) for the highest compared to
the lowest BMI quintile.
Relative weight changes and AF risk
The number of patients with AF was 49 (4.8%) in the
weight gain group, 139 (3.7%) in the stable group and 99
(4.1%) in the weight loss group, and the unadjusted inci-
dence rates of AF (per 1,000 patient years) were 11.6
(8.6 – 15.1), 9.0 (7.6 – 10.6) and 10.2 (8.3 – 12.3), respect-
ively. The risk of incident AF in adjusted analyses were
Table 2 Relative risks of atrial fibrillation in hazard ratios according to baseline BMI groups and quintiles
Atrial fibrillation
Number of events (%) Hazard ratio (95% CI)
Total (n = 7169) 287 (4.0)
BMI groups:
BMI < 25 (n = 750) 17 (2.3) 1.00 Reference
BMI 25–30 (n = 2579) 100 (3.9) 1.85 (1.10–3.09)
BMI≥ 30 (n = 3840) 170 (4.4) 2.85 (1.73–4.71)
BMI quintiles:
Q1 -BMI≤ 26.2 (n = 1278) 30 (2.3) 1.00 Reference
Q2 -BMI 26.3-28.7 (n = 1366) 56 (4.1) 1.78 (1.14-2.77)
Q3 -BMI 28.8-31.3 (n = 1486) 59 (4.0) 1.91 (1.23-2.97)
Q4 -BMI 31.4-34.8 (n = 1489) 70 (4.7) 2.63 (1.71-4.04)
Q5 -BMI≥ 34.9 (n = 1550) 72 (4.6) 3.52 (2.29-5.43)
Adjusted for age, gender, systolic blood pressure and previous angina pectoris. CI = confidence interval, BMI = body mass index, Q = quintiles.
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creased than in the stable weight group in model A, and
almost identical in model B (Table 3). The AF risk was not
different in patients with weight loss compared to those
with stable weight. The adjusted cumulative incidence
curves in Figure 3a) demonstrate that the increased rate of
AF in the weight gain group is apparent at approximately
1 year with full separation at year 2; beyond this point
in time the curves for weight gain, respectively stable
weight seem parallel. In the subgroup of patients with
BMI ≥ 30 kg/m2 at baseline (n =3,840), 170 AF eventsFigure 2 Shows cumulative hazard of AF according to baseline
BMI groups (WHO classification) adjusted for age, gender and
systolic BP.occurred during follow-up. The weight gain patients
had a comparable relative risk of AF (1.6-fold, 1.0-2.5)
in this obese subgroup (Table 3 and Figure 3b).
We also explored if there was any difference between
genders and found similar gradual risk increase of AF
with higher baseline BMI. Generally the incidence of AF
among women in our cohort was lower than among
men with unadjusted incidence rates of AF in the weight
gain group 14.4 (10.1 – 19.8) per 1,000 patient years in
men and 8.0 (4.7 – 12.9) in women. In the Cox analyses
(model B without adjustment for gender) the association
between weight gain and AF risk was still significantly
higher compared with the stable weight group in men, but
not in women, possibly influenced by reduced statistical
power (hazard ratio 1.6, 1.1-2.4 in men and 1.4, 0.8-2.5 in
women).
Discussion
In this large primary care based cohort of type 2 diabetes
patients, we observed a close association between body
weight – in terms of both baseline BMI and weight
change during the first 18 months after diabetes diagno-
sis – and the subsequent development of AF. Over-
weight and obese patients had nearly doubled and
tripled AF risk, respectively, compared to normal-weight
patients. Patients with early weight gain had a 1.5-fold
risk of incident AF compared to those who kept a stable
weight. The AF risk was generally lower in women and
the association between AF risk and weight gain only
reached statistical significance in men.
AF and diabetes often co-exist [4,7,14,17]. Most studies
show that diabetes is associated with a higher risk of AF,
although the results have been somewhat conflicting
[15,16]. Also in our study we found a high incidence rate
of AF (9.7 per 1,000 patient years) during up to 9 years
follow-up in more than 7,000 predominantly middle-aged
Table 3 Relative risks of atrial fibrillation in hazard ratios according to weight change groups
All Weight gain Stable weight Weight loss
Total cohort
-number of patients 7169 1023 3736 2410
-number of AF events 287 49 139 99
Model A: Hazard ratio (95% CI) 1.54 (1.11–2.14) 1.00 Reference 1.07 (0.82–1.39)
Model B: Hazard ratio (95% CI) 1.53 (1.10–2.12) 1.00 Reference 1.06 (0.81–1.38)
Subgroup with BMI ≥ 30
-number of patients 3840 468 1790 1582
-number of AF events 170 27 78 65
Model A: Hazard ratio (95% CI) 1.60 (1.03–2.49) 1.00 Reference 0.94 (0.67–1.31)
Model B: Hazard ratio (95% CI) 1.59 (1.02–2.47) 1.00 Reference 0.93 (0.67–1.30)
Model A: Adjustments for age, gender, body mass index at baseline and previous angina pectoris. Model B: Adjustments as in Model A + systolic blood pressure;
included imputation of missing blood pressure data. AF = atrial fibrillation, CI = confidence interval, BMI = body mass index.
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centers. The importance of body weight for the increased
AF burden in diabetes is not well described, but one
case–control study has indicated that the relationship
between BMI and AF was stronger in patients with
diabetes than in those without [13]. Accordingly, in our
diabetic cohort there was a consistent and gradual risk
increase of AF with increasing baseline BMI, and the
associations between obesity and AF risk compared
with normal BMI were of larger magnitude (hazard ratio
2.9) than previously shown in the general population
(hazard ratios, obesity vs. normal BMI varying from 1.3
to 2.3 in different studies) [9,24].
In The Swedish Primary Prevention Study, weight gain
from age 20 to midlife compared with stable weight was an
independent long-term predictor of AF [10]. Among femaleFigure 3 Shows cumulative hazard of AF according to weight change
adjusted for age, gender, BMI at baseline, previous AP and systolic B
baseline obesity.healthcare professionals in the Women’s Health Study a
change in weight category during the first 5 years of follow-
up was associated with a slightly higher AF risk in subjects
who progressed from non-obese (BMI <30 kg/m2) to obese
weight category, than in those who were obese both at
baseline and follow-up [12]. In the present study we also
observed that short-term weight gain was associated with
an increased AF risk, whereas weight loss did not lower the
risk. To be noticed in our cohort, is that the weight loss
group started with the highest baseline BMI, and after
reduction their BMI was still >30 kg/m2. Although we
made adjustments for baseline BMI, the patients with initial
weight loss stabilized their weight during follow-up, while
the stable weight group showed a steady decrease.
Obesity has been associated with impaired left ventricu-
lar diastolic function and left atrial dilatation, which maygroups during the first 18 months after diabetes diagnosis
P in a) the total cohort, and b) the subgroup of patients with
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the association of BMI with AF risk became insignificant
after adjustments for left atrium size, leading to the con-
clusion that left atrium enlargement due to obesity
accounted for the entire observed risk association with AF
[9]. Body size, and thus obesity, is considered to be one of
the most important determinants of left atrial dimension
[25]. In patients with diabetes, obesity – as compared to
normal weight – appears to be even more important for
AF development than in the non-diabetic population. The
relationship between diabetes, obesity and incident AF
is not fully understood, but both diabetes and high body
weight may be causally related to increased risk of AF
through pathophysiological processes resulting in struc-
tural and electrical remodelling of the heart, influencing
the AF substrate [3,26]. Incident AF appears more com-
mon in diabetic patients, suggesting additional effects of
e.g. insulin resistance, inflammation or autonomic changes,
which may act as AF mediators. Insulin resistance in type 2
diabetes – also a key characteristic of obesity – is associated
with hypertension and left ventricular hypertrophy. Fur-
thermore, both obesity and diabetes are associated with
underlying autonomic disturbances that may also influence
atrial arrhythmogenicity, thereby facilitating local AF trig-
gers [14,15].Strengths and limitations
The strengths of the ROSE study include the large num-
ber of patients with newly diagnosed type 2 diabetes in a
genuine clinical setting in primary health care, and the
mean 4.6-year follow-up period for endpoint measure-
ments recorded in nationwide health care registries.
Limitations of the study include missing data on diet,
waist circumference and physical activity in our database.
The baseline demographics show more common use of
sulfonylurea and insulin in the weight gain group. Regret-
fully, we did not have statistical power to explore the
potential influence of each glucose lowering drug separ-
ately, which might be relevant as some drugs (ie. met-
formin) are reported to slightly reduce weight and others
(sulfonylurea and insulin) to increase weight [27]. A very
recent study found that among patients with type 2
diabetes in Taiwan, metformin use was associated with a
decreased risk of AF [28]. Antihypertensive medication
during follow-up might also influence the risk of incident
AF independently of weight change [29].
We did not perform analysis with adjustments for the
competing risk of death. Previous results from the same
cohort has shown that weight gain increases CVD mor-
tality, indicating that mortality may be a competing risk
in the analyses of AF incidence; hence the weight gain-
AF association may be even higher than those observed
in the present study [20].Conclusion and clinical implications
In primary care patients with newly diagnosed type 2
diabetes, the overweight and obese patients had nearly
doubled and tripled risk of AF, respectively, compared to
the normal-weight patients. Additionally, a modest weight
gain during the first 18 months after diabetes diagnosis
was associated with an increased risk of incident AF. It is
possible that prevention of further weight gain, especially
among already obese persons with newly diagnosed type 2
diabetes, is particularly important to prevent increased
AF risk. This finding might also influence the choice of
glucose lowering medication as some drugs are reported
to have a beneficial impact on weight.
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